News / Taiwan / economic_daily
Joyo Pharm Reports 50% Revenue Surge in August
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-09-08
4114
Joyo Pharmaceutical announced a 50% year-over-year revenue increase for August, driven by strong sales in oncology, cardiovascular, and women's health products.
What Happened
Revenue Growth: Joyo Pharmaceutical reported August revenue of NT$750 million, marking a 50% year-over-year increase, with cumulative revenue for the first eight months up 26% to NT$5.096 billion.
Product Performance: Growth was fueled by robust demand for oncology, cardiovascular, and women's health products, alongside strong sales of nasal sprays and long-acting hormonal treatments.
International Expansion: The company has finalized a distribution partnership in Vietnam and received PMDA certification for its hormone manufacturing facility in Japan, strengthening its Asian market presence.
Future Outlook: Management expects continued momentum from seasonal demand for allergy medications and the clinical adoption of its unique long-acting hormonal therapies for prostate cancer and precocious puberty.